Udit Chaddha, MD
Pulmonary Disease · New York, NYNPI 1548524523
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $21,064 with a category attached, or 71.2%. Boston Scientific accounts for 71.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $20,467 and has fallen 99.6% since, to $90 in 2024. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $638.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Intuitive Surgical$2K
- Covidien LP$2K
- Pinnacle Biologics, Inc$357
- Johnson & Johnson$329
- Steris Corporation$233
- plus $296 from 4 others
What the payments were for
- Speaking & faculty fees$2001%
- Grants$15,00071%
- Travel & lodging$3,81118%
- Food & beverage$2,05310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $15,034 |
| Intuitive Surgical | 10 | $2,431 |
| Covidien LP | 6 | $2,385 |
| Pinnacle Biologics, Inc | 6 | $357 |
| Johnson & Johnson | 2 | $329 |
| Steris Corporation | 1 | $233 |
| Auris Health, Inc. | 1 | $122 |
| Ambu Inc. | 1 | $73 |
| Olympus America Inc. | 1 | $58 |
| Olympus Corporation Of The Americas | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PULMONARY$15,000
- superDimension$2,337
- Da Vinci Surgical System$2,266
- MONARCH$282
- TRUFREEZE$233
- Photofrin$200
- Monarch Platform$169
How this compares
$21,064 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,199 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,306 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,061 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.